**Clinical relevance of elevated soluble ST2, HSP27 and 20S proteasome in patients with COVID-19**

Ralph Wendt1 \*, Marie-Therese Lingitz2,3\*, Maria Laggner2, Michael Mildner2,4 Denise Traxler2,5, Alexandra Graf6, Pavla Krotka6, Bernhard Moser2,7,, Konrad Hoetzenecker7, Sven Kalbitz1, Christoph Lübbert1,8, Joachim Beige1,9, Hendrik Jan Ankersmit2,7

\* contributed equally

1 Department of Infectious Diseases, Tropical Medicine, Nephrology and Rheumatology, St. Georg Hospital, Delitzscher Str. 141, D-04129 Leipzig, Germany

2 Laboratory for Cardiac and Thoracic Diagnosis, Department of Surgery, Regeneration and Applied Immunology, Medical University of Vienna, Research Laboratories Vienna General Hospital, Waehringer Guertel 18-20, 1090 Vienna, Austria

3 Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria

4 Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria

5 Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria

6 Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Spitalg. 23, 1090 Vienna, Austria

7 Division of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria

8 Division of Infectious Diseases and Tropical Medicine, Department of Medicine II, Leipzig University Medical Center, Liebigstr. 20, D-04103 Leipzig, Germany

9 Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany

Corresponding author:

HJ Ankersmit

Department of Thoracic Surgery, Medical University of Vienna

Waehringer Guertel 18-20

1090 Vienna, Austria

phone: +43-(0)1-40400-67770

e-mail: hendrik.ankersmit@meduniwien.ac.at

# Supplementary Material

## **Figure S1** ROC Curves for the endpoint 30-day mortality of investigated parameters

## **Figure S2** ROC Curves for the endpoint 60-day mortality of investigated parameters



## Figure S3 ROC Curves for the endpoint 90-day mortality of investigated parameters

 

## Figure S4 ROC Curves for the endpoint in-hospital mortality of investigated parameters



## Table S1 AUC of ROC curves for the endpoint 30-day mortality of investigated parameters

|  |  |  |
| --- | --- | --- |
|  | **AUC** | **95%CI** |
| HSP27 | 0.6003 | 0.5052-0.6954 |
| sST2 | 0.6974 | 0.6117-0.7830 |
| TNFR1 | 0.5666 | 0.4766-0.6566 |
| CK18 | 0.5479 | 0.4520-0.6438 |
| 20S proteasome | 0.6149 | 0.5161-0.7136 |

## Table S2 AUC of ROC curves for the endpoint 60-day mortality of investigated parameters

|  |  |  |
| --- | --- | --- |
|  | **AUC** | **95%CI** |
| HSP27 | 0.5963  | 0.5091-0.6836 |
| sST2 | 0.6710  | 0.5834-0.7586 |
| TNFR1 | 0.5634  | 0.4739-0.6528 |
| CK18 | 0.5464  | 0.4581-0.6348 |
| 20S proteasome | 0.6046  | 0.5131-0.6962 |

## Table S3 AUC of ROC curves for the endpoint 90-day mortality of investigated parameters

|  |  |  |
| --- | --- | --- |
|  | **AUC** | **95%CI** |
| HSP27 | 0.6055  | 0.5178-0.6933 |
| sST2 | 0.6750  | 0.5871-0.7628 |
| TNFR1 | 0.5740 | 0.4828-0.6651 |
| CK18 | 0.5459 | 0.4567-0.6352 |
| 20S proteasome | 0.5875  | 0.4935-0.6815 |

## Table S4 AUC of ROC curves for the endpoint in-hospital mortality of investigated parameters

|  |  |  |
| --- | --- | --- |
|  | **AUC** | **95%CI** |
| HSP27 | 0.5909  | 0.4928-0.6890 |
| sST2 | 0.7292  | 0.6476-0.8108 |
| TNFR1 | 0.5705  | 0.4761-0.6650 |
| CK18 | 0.5907  | 0.4935-0.6879 |
| 20S proteasome | 0.6610 | 0.5656-0.7565 |